Tags

Type your tag names separated by a space and hit enter

Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
J Nanobiotechnology. 2016 Jun 08; 14(1):41.JN

Abstract

BACKGROUND

It is difficult to discriminate healthy subjects and patients with Parkinson disease (PD) or Parkinson disease dementia (PDD) by assaying plasma α-synuclein because the concentrations of circulating α-synuclein in the blood are almost the same as the low-detection limit using current immunoassays, such as enzyme-linked immunosorbent assay. In this work, an ultra-sensitive immunoassay utilizing immunomagnetic reduction (IMR) is developed. The reagent for IMR consists of magnetic nanoparticles functionalized with antibodies against α-synuclein and dispersed in pH-7.2 phosphate-buffered saline. A high-Tc superconducting-quantum-interference-device (SQUID) alternative-current magnetosusceptometer is used to measure the IMR signal of the reagent due to the association between magnetic nanoparticles and α-synuclein molecules.

RESULTS

According to the experimental α-synuclein concentration dependent IMR signal, the low-detection limit is 0.3 fg/ml and the dynamic range is 310 pg/ml. The preliminary results show the plasma α-synuclein for PD patients distributes from 6 to 30 fg/ml. For PDD patients, the concentration of plasma α-synuclein varies from 0.1 to 100 pg/ml. Whereas the concentration of plasma α-synuclein for healthy subjects is significantly lower than that of PD patients.

CONCLUSIONS

The ultra-sensitive IMR by utilizing antibody-functionalized magnetic nanoparticles and high-Tc SQUID magnetometer is promising as a method to assay plasma α-synuclein, which is a potential biomarker for discriminating patients with PD or PDD.

Authors+Show Affiliations

MagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan. syyang@magqu.com. Institute of Electro-optical Science and Technology, National Taiwan Normal University, Taipei, 116, Taiwan. syyang@magqu.com.Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan. Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, 100, Taiwan. Department of Psychology, National Taiwan University, Taipei, 100, Taiwan. Graduate Institute of Biomedical Engineering and Bioinformatics, National Taiwan University, Taipei, 116, Taiwan.Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.Institute of Electro-optical Science and Technology, National Taiwan Normal University, Taipei, 116, Taiwan.MagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.Institute of Electro-optical Science and Technology, National Taiwan Normal University, Taipei, 116, Taiwan.MagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.MagQu Co., Ltd., Xindian District, New Taipei City, 231, Taiwan.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

27278241

Citation

Yang, Shieh-Yueh, et al. "Development of an Ultra-high Sensitive Immunoassay With Plasma Biomarker for Differentiating Parkinson Disease Dementia From Parkinson Disease Using Antibody Functionalized Magnetic Nanoparticles." Journal of Nanobiotechnology, vol. 14, no. 1, 2016, p. 41.
Yang SY, Chiu MJ, Lin CH, et al. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnology. 2016;14(1):41.
Yang, S. Y., Chiu, M. J., Lin, C. H., Horng, H. E., Yang, C. C., Chieh, J. J., Chen, H. H., & Liu, B. H. (2016). Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. Journal of Nanobiotechnology, 14(1), 41. https://doi.org/10.1186/s12951-016-0198-5
Yang SY, et al. Development of an Ultra-high Sensitive Immunoassay With Plasma Biomarker for Differentiating Parkinson Disease Dementia From Parkinson Disease Using Antibody Functionalized Magnetic Nanoparticles. J Nanobiotechnology. 2016 Jun 8;14(1):41. PubMed PMID: 27278241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. AU - Yang,Shieh-Yueh, AU - Chiu,Ming-Jang, AU - Lin,Chin-Hsien, AU - Horng,Herng-Er, AU - Yang,Che-Chuan, AU - Chieh,Jen-Jie, AU - Chen,Hsin-Hsien, AU - Liu,Bing-Hsien, Y1 - 2016/06/08/ PY - 2015/12/22/received PY - 2016/05/24/accepted PY - 2016/6/10/entrez PY - 2016/6/10/pubmed PY - 2017/2/14/medline KW - Immunomagnetic reduction KW - Parkinson disease KW - α-synuclein SP - 41 EP - 41 JF - Journal of nanobiotechnology JO - J Nanobiotechnology VL - 14 IS - 1 N2 - BACKGROUND: It is difficult to discriminate healthy subjects and patients with Parkinson disease (PD) or Parkinson disease dementia (PDD) by assaying plasma α-synuclein because the concentrations of circulating α-synuclein in the blood are almost the same as the low-detection limit using current immunoassays, such as enzyme-linked immunosorbent assay. In this work, an ultra-sensitive immunoassay utilizing immunomagnetic reduction (IMR) is developed. The reagent for IMR consists of magnetic nanoparticles functionalized with antibodies against α-synuclein and dispersed in pH-7.2 phosphate-buffered saline. A high-Tc superconducting-quantum-interference-device (SQUID) alternative-current magnetosusceptometer is used to measure the IMR signal of the reagent due to the association between magnetic nanoparticles and α-synuclein molecules. RESULTS: According to the experimental α-synuclein concentration dependent IMR signal, the low-detection limit is 0.3 fg/ml and the dynamic range is 310 pg/ml. The preliminary results show the plasma α-synuclein for PD patients distributes from 6 to 30 fg/ml. For PDD patients, the concentration of plasma α-synuclein varies from 0.1 to 100 pg/ml. Whereas the concentration of plasma α-synuclein for healthy subjects is significantly lower than that of PD patients. CONCLUSIONS: The ultra-sensitive IMR by utilizing antibody-functionalized magnetic nanoparticles and high-Tc SQUID magnetometer is promising as a method to assay plasma α-synuclein, which is a potential biomarker for discriminating patients with PD or PDD. SN - 1477-3155 UR - https://www.unboundmedicine.com/medline/citation/27278241/Development_of_an_ultra_high_sensitive_immunoassay_with_plasma_biomarker_for_differentiating_Parkinson_disease_dementia_from_Parkinson_disease_using_antibody_functionalized_magnetic_nanoparticles_ L2 - https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-016-0198-5 DB - PRIME DP - Unbound Medicine ER -